Search

Your search keyword '"Leis J"' showing total 791 results
Start Over Author "Leis J"
791 results on '"Leis J"'

4. Specimen collection: An essential tool

Author

Rocha, L. A., Aleixo, A., Allen, G., Almeda, F., Baldwin, C. C., Barclay, M. V. L., Bates, J. M., Bauer, A. M., Benzoni, F., Berns, C. M., Berumen, M. L., Blackburn, D. C., Blum, S., Bolaños, F., Bowie, R. C. K., Britz, R., Brown, R. M., Cadena, C. D., Carpenter, K., Ceríaco, L. M., Chakrabarty, P., Chaves, G., Choat, J. H., Clements, K. D., Collette, B. B., Collins, A., Coyne, J., Cracraft, J., Daniel, T., de Carvalho, M. R., de Queiroz, K., Di Dario, F., Drewes, R., Dumbacher, J. P., Engilis, A., Erdmann, M. V., Eschmeyer, W., Feldman, C. R., Fisher, B. L., Fjeldså, J., Fritsch, P. W., Fuchs, J., Getahun, A., Gill, A., Gomon, M., Gosliner, T., Graves, G. R., Griswold, C. E., Guralnick, R., Hartel, K., Helgen, K. M., Ho, H., Iskandar, D. T., Iwamoto, T., Jaafar, Z., James, H. F., Johnson, D., Kavanaugh, D., Knowlton, N., Lacey, E., Larson, H. K., Last, P., Leis, J. M., Lessios, H., Liebherr, J., Lowman, M., Mahler, D. L., Mamonekene, V., Matsuura, K., Mayer, G. C., Mays, H., McCosker, J., McDiarmid, R. W., McGuire, J., Miller, M. J., Mooi, R., Mooi, R. D., Moritz, C., Myers, P., Nachman, M. W., Nussbaum, R. A., Foighil, D. Ó, Parenti, L. R., Parham, J. F., Paul, E., Paulay, G., Pérez-Emán, J., Pérez-Matus, A., Poe, S., Pogonoski, J., Rabosky, D. L., Randall, J. E., Reimer, J. D., Robertson, D. R., Rödel, M.-O., Rodrigues, M. T., Roopnarine, P., Rüber, L., Ryan, M. J., Sheldon, F., Shinohara, G., Short, A., Simison, W. B., Smith-Vaniz, W. F., Springer, V. G., Stiassny, M., Tello, J. G., Thompson, C. W., Trnski, T., Tucker, P., Valqui, T., Vecchione, M., Verheyen, E., Wainwright, P. C., Wheeler, T. A., White, W. T., Will, K., Williams, J. T., Williams, G., Wilson, E. O., Winker, K., Winterbottom, R., and Witt, C. C.

Published
2014

5. P1094: CHARACTERISTICS, MANAGEMENT, AND OUTCOMES OF PATIENTS WITH T-CELL LARGE GRANULAR LYMPHOCYTIC LEUKEMIA AT A LARGE TERTIARY CARE CENTER

Author

Audil, H., primary, Shah, M., additional, Rabe, K., additional, Ding, W., additional, Hampel, P., additional, Bennani, N. N., additional, Call, T., additional, Hanson, C., additional, Wang, Y., additional, Koehler, A., additional, Schwager, S., additional, Leis, J., additional, Slager, S., additional, Kenderian, S., additional, Al-Kali, A., additional, Nowakowski, G., additional, Shi, M., additional, and Parikh, S., additional

Published
2022
Full Text
View/download PDF

6. P656: INCIDENT VENOUS THROMBOEMBOLISM (VTE) IN PATIENTS WITH MONOCLONAL B-CELL LYMPHOCYTOSIS (MBL) AND CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) – A POPULATION-BASED STUDY

Author

Koehler, A., primary, Moise, M., additional, Call, T., additional, Rabe, K., additional, Achenbach, S., additional, Crusan, D., additional, Bailey, K., additional, Petterson, T., additional, Ding, W., additional, Kenderian, S., additional, Leis, J., additional, Wang, Y., additional, Muchtar, E., additional, Hampel, P., additional, Schwager, S., additional, Slager, S., additional, Kay, N., additional, Ashrani, A., additional, and Parikh, S., additional

Published
2022
Full Text
View/download PDF

11. Reactions in Micelles, Monolayers, and Liquid Crystals

Author

Romsted, Laurence S., Perez-Benito, E., Rodenas, E., Shukla, Alka, Shukla, Shyam S., Katiyar, S. S., Kumar, Ajay, Behera, G. B., Minch, M. J., Dennis, Jason, Bommarlusp, A., Miothe, P., Voss, H., Singh, C. P., Shah, D. O., Abuin, E., Lissi, E., Reinsborough, V. C., Stultz, T. D. M., Xiang, X., Thompson, R. A., Allenmark, S. G., Bommarius, A. S., Wang, D. I. C., Hatton, T. A., Sarcar, Shraboni, Jain, Tanoj Kumar, Maitra, Amarnath, Wilcoxon, J. P., Williamson, R. L., Grancaric, A. M., Kallay, N., Bravo, C., Hervés, P., Leis, J. R., Peña, M. E., Shanker, R., Sharma, Neeta, Bakore, G. V., Chawla, H. Mohindra, Pathak, M., Johny, C. J., O’Sullivan, E., Yang, Y., Ward, A. J. I., Mittal, K. L., editor, and Shah, D. O., editor

Published
1991
Full Text
View/download PDF

16. Immunophenotypic and gene expression analysis of monoclonal B-cell lymphocytosis shows biologic characteristics associated with good prognosis CLL

Author

Lanasa, M C, Allgood, S D, Slager, S L, Dave, S S, Love, C, Marti, G E, Kay, N E, Hanson, C A, Rabe, K G, Achenbach, S J, Goldin, L R, Camp, N J, Goodman, B K, Vachon, C M, Spector, L G, Rassenti, L Z, Leis, J F, Gockerman, J P, Strom, S S, Call, T G, Glenn, M, Cerhan, J R, Levesque, M C, Weinberg, J B, and Caporaso, N E

Published
2011
Full Text
View/download PDF

20. Specimen collection: An essential tool

Author

Sills, Jennifer, Rocha, L. A., Aleixo, A., Allen, G., Almeda, F., Baldwin, C. C., Barclay, M. V.L., Bates, J. M., Bauer, A. M., Benzoni, F., Berns, C. M., Berumen, M. L., Blackburn, D. C., Blum, S., Bolaños, F., Bowie, R. C. K., Britz, R., Brown, R. M., Cadena, C. D., Carpenter, K., Ceríaco, L. M., Chakrabarty, P., Chaves, G., Choat, J. H., Clements, K. D., Collette, B. B., Collins, A., Coyne, J., Cracraft, J., Daniel, T., de Carvalho, M. R., de Queiroz, K., Di Dario, F., Drewes, R., Dumbacher, J. P., Engilis, A., Jr., Erdmann, M. V., Eschmeyer, W., Feldman, C. R., Fisher, B. L., Fjeldså, J., Fritsch, P. W., Fuchs, J., Getahun, A., Gill, A., Gomon, M., Gosliner, T., Graves, G. R., Griswold, C. E., Guralnick, R., Hartel, K., Helgen, K. M., Ho, H., Iskandar, D. T., Iwamoto, T., Jaafar, Z., James, H. F., Johnson, D., Kavanaugh, D., Knowlton, N., Lacey, E., Larson, H. K., Last, P., Leis, J. M., Lessios, H., Liebherr, J., Lowman, M., Mahler, D. L., Mamonekene, V., Matsuura, K., Mayer, G. C., Mays, H., Jr., McCosker, J., McDiarmid, R. W., McGuire, J., Miller, M. J., Mooi, R., Mooi, R. D., Moritz, C., Myers, P., Nachman, M. W., Nussbaum, R. A., Foighil, D. Ó, Parenti, L. R., Parham, J. F., Paul, E., Paulay, G., Pérez-Emán, J., Pérez-Matus, A., Poe, S., Pogonoski, J., Rabosky, D. L., Randall, J. E., Reimer, J. D., Robertson, D. R., Rödel, M.-O., Rodrigues, M. T., Roopnarine, P., Rüber, L., Ryan, M. J., Sheldon, F., Shinohara, G., Short, A., Simison, W. B., Smith-Vaniz, W. F., Springer, V. G., Stiassny, M., Tello, J. G., Thompson, C. W., Trnski, T., Tucker, P., Valqui, T., Vecchione, M., Verheyen, E., Wainwright, P. C., Wheeler, T. A., White, W. T., Will, K., Williams, J. T., Williams, G., Wilson, E. O., Winker, K., Winterbottom, R., and Witt, C. C.

Published
2014

37. Bromine-AOT charge-transfer complexes and hydrogen-bond donor ability of water on AOT-isooctane-H2O reverse micelles and water-in-oil microemulsions

Author

Garcia-Rio, Luis, Mejuto, Juan C., Ciri, Renata, Blagoeva, Iva B., Leis, J. Ramon, and Ruasse, Marie-Francoise

Subjects
Electron donor-acceptor complexes -- Research, Charge transfer -- Research, Chemistry, Physical and theoretical -- Research, Bromine -- Research, Micelles -- Research, Water -- Ion exchange process, Chemicals, plastics and rubber industries
Abstract

Reactions involving sodium bis(2ethylhexyl)sulfosuccinate (AOT) have been found to be useful as a surfactant that spontaneously aggregates into reverse micelles and water-in-oil microemulsions without the aid of a cosurfactant. Experiments in isooctane have revealed the presence of a charge transfer complex between bromine and monomeric AOT. This is in agreement with a very strong donor ability of AOT due to its sulfonate headgroup.

Published
1999

44. PS1162 COMBINATION THERAPY TO PREVENT IBRUTINIB WITHDRAWAL: CONTINUED IBRUTINIB WITH THE ADDITION OF VENETOCLAX AT TIME OF PROGRESSION IN IBRUTINIB-TREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

Author

Hampel, P., primary, Call, T., additional, Ding, W., additional, Muchtar, E., additional, Kenderian, S., additional, Leis, J., additional, Witzig, T., additional, Koehler, A., additional, Fonder, A., additional, Schwager, S., additional, Rabe, K., additional, Slager, S., additional, Kay, N., additional, and Parikh, S., additional

Published
2019
Full Text
View/download PDF

48. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS) : a randomised, double-blind, phase 3 study

Author

Chanan-Khan, Asher, Cramer, Paula, Demirkan, Fatih, Fraser, Graeme, Silva, Rodrigo Santucci, Grosicki, Sebastian, Pristupa, Aleksander, Janssens, Ann, Mayer, Jiri, Bartlett, Nancy L, Dilhuydy, Marie-Sarah, Pylypenko, Halyna, Loscertales, Javier, Avigdor, Abraham, Rule, Simon, Villa, Diego, Samoilova, Olga, Panagiotidis, Panagiots, Goy, Andre, Mato, Anthony, Pavlovsky, Miguel A, Karlsson, Claes, Mahler, Michelle, Salman, Mariya, Sun, Steven, Phelps, Charles, Balasubramanian, Sriram, Howes, Angela, Hallek, Michael, Assouline, S, Bence-Bruckler, I, Buckstein, R, Fraser, G, Larratt, L, Minuk, L, Villa, D, Angevine, A, Bartlett, N, Bixby, D, Caimi, P, Chanan-Khan, A, Craig, M, Forero-Torres, A, Ganguly, S, Goy, A, Heffner, L, Hermann, R, Lansigan, F, Leis, J, Letzer, J, Link, B, Liu, D, McCaul, K, McGuire, E, Skinner, W, Starodub, A, Stuart, R, Thirman, M, Tirumali, N, Yang, J, Janssens, A, Offner, F, Van den Neste, E, Van Hoof, A, Mayer, J, Novak, J, Trneny, M, Cartron, G, Dartigeas, C, Dilhuydy, M, Ghez, D, Haioun, C, Leblond, V, Salles, G, Balser, C, Cramer, P, Dreger, P, Durig, J, Eckart, M, Heinrich, B, Illmer, T, Jentsch-Ullrich, K, Pfreundschuh, M, Schetelig, J, Schlag, R, Soling, U, Stilgenbauer, S, Anagnostopoulos, A, Dimopoulos, A, Panagiotidis, P, Vrakidou, E, Bairey, O, Yehuda, D Ben, Braester, A, Fineman, R, Herishanu, Y, Nagler, A, Ruchlemer, R, Tadmor, T, Grosicki, S, Homenda, W, Jurczak, W, Pluta, A, Woszczyk, D, Espirito Santo, A, Luis, R, Raposo, J, Viveiros, C, Alexeeva, J, Dunaev, Y, Golubeva, M, Khuageva, N, Loginov, A, Lysenko, I, Osmanov, E, Pavlov, V, Pristupa, A, Proydakov, A, Rossiev, V, Samarina, I, Samoilova, O, Serduk, O, Shneider, T, Udovitsa, D, Voloshin, S, Gayoso, J, Gonzalez, M, Gonzalez Barca, E, Hernandez Rivas, J, Jargue, I, Loscertales, J, Karlsson, C, Sender, M, Aktan, M, Arslan, O, Demirkan, F, Ferhanoglu, B, Kaynar, L, Sayinalp, N, Vaural, F, Yagci, M, Dyagil, I, Kaplan, P, Masliak, Z, Oliynyk, H, Popovska, T, Pylypenko, H, Rekhtman, G, Dearden, C, Morley, N, Moss, P, Rule, S, Pavlovsky, M, Riveros, D, Santucci-Silva, R, Romeo, M, Scheliga, A, Salazar, L, Gomez, D, Ramirez, E, and Jung, C

Subjects
Male, Medizin, Gastroenterology, chemistry.chemical_compound, 0302 clinical medicine, Piperidines, immune system diseases, hemic and lymphatic diseases, Antineoplastic Combined Chemotherapy Protocols, Atrial Fibrillation, Bendamustine Hydrochloride, Aged, 80 and over, Anemia, Nausea, Middle Aged, 3. Good health, Fludarabine, Intention to Treat Analysis, Oncology, 030220 oncology & carcinogenesis, Ibrutinib, Retreatment, Disease Progression, Rituximab, Female, medicine.drug, Bendamustine, Adult, medicine.medical_specialty, Neutropenia, Hemorrhage, Disease-Free Survival, 03 medical and health sciences, Double-Blind Method, Internal medicine, medicine, Humans, Aged, Performance status, business.industry, Adenine, medicine.disease, Interim analysis, Leukemia, Lymphocytic, Chronic, B-Cell, Thrombocytopenia, Surgery, Regimen, Pyrimidines, chemistry, Pyrazoles, Mantle cell lymphoma, business, 030215 immunology
Abstract

Most patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma relapse after initial therapy. Bendamustine plus rituximab is often used in the relapsed or refractory setting. We assessed the efficacy and safety of adding ibrutinib, an oral covalent inhibitor of Bruton's tyrosine kinase (BTK), to bendamustine plus rituximab in patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma.The HELIOS trial was an international, double-blind, placebo-controlled, phase 3 study in adult patients (≥18 years of age) who had active chronic lymphocytic leukaemia or small lymphocytic lymphoma with measurable lymph node disease (1·5 cm) by CT scan, and had relapsed or refractory disease following one or more previous lines of systemic therapy consisting of at least two cycles of a chemotherapy-containing regimen, an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1, and adequate bone marrow, liver, and kidney function. Patients with del(17p) were excluded because of known poor response to bendamustine plus rituximab. Patients who had received previous treatment with ibrutinib or other BTK inhibitors, refractory disease or relapse within 24 months with a previous bendamustine-containing regimen, or haemopoietic stem-cell transplant were also excluded. Patients were randomly assigned (1:1) by a web-based system to receive bendamustine plus rituximab given in cycles of 4 weeks' duration (bendamustine: 70 mg/m(2) intravenously on days 2-3 in cycle 1, and days 1-2 in cycles 2-6; rituximab: 375 mg/m(2) on day 1 of cycle 1, and 500 mg/m(2) on day 1 of cycles 2-6 for a maximum of six cycles) with either ibrutinib (420 mg daily orally) or placebo until disease progression or unacceptable toxicity. Patients were stratified according to whether they were refractory to purine analogues and by number of previous lines of therapy. The primary endpoint was independent review committee (IRC)-assessed progression-free survival. Crossover to ibrutinib was permitted for patients in the placebo group with IRC-confirmed disease progression. Analysis was by intention-to-treat and is continuing for further long-term follow-up. The trial is registered with ClinicalTrials.gov, number NCT01611090.Between Sept 19, 2012, and Jan 21, 2014, 578 eligible patients were randomly assigned to ibrutinib or placebo in combination with bendamustine plus rituximab (289 in each group). The primary endpoint was met at the preplanned interim analysis (March 10, 2015). At a median follow-up of 17 months (IQR 13·7-20·7), progression-free survival was significantly improved in the ibrutinib group compared with the placebo group (not reached in the ibrutinib group (95% CI not evaluable) vs 13·3 months (11·3-13·9) in the placebo group (hazard ratio [HR] 0·203, 95% CI 0·150-0·276; p0·0001). IRC-assessed progression-free survival at 18 months was 79% (95% CI 73-83) in the ibrutinib group and 24% (18-31) in the placebo group (HR 0·203, 95% CI 0·150-0·276; p0·0001). The most frequent all-grade adverse events were neutropenia and nausea. 222 (77%) of 287 patients in the ibrutinib group and 212 (74%) of 287 patients in the placebo group reported grade 3-4 events; the most common grade 3-4 adverse events in both groups were neutropenia (154 [54%] in the ibrutinib group vs 145 [51%] in the placebo group) and thrombocytopenia (43 [15%] in each group). A safety profile similar to that previously reported with ibrutinib and bendamustine plus rituximab individually was noted.In patients eligible for bendamustine plus rituximab, the addition of ibrutinib to this regimen results in significant improvements in outcome with no new safety signals identified from the combination and a manageable safety profile.Janssen ResearchDevelopment.

Published
2016

50. Mechanism for basic hydrolysis of N-nitrosoguanidines in aqueous solution

Author

Garcia-Rio, L., Leis, J. R., Moreira, J. A., Araujo, E., Norberto, F., and Ribeiro, L.

Subjects
Chemistry, Organic -- Research, Organic compounds -- Composition, Hydrolysis -- Analysis, Solution (Chemistry), Guanfacine, Nitroso compounds -- Composition, Chemical reaction, Rate of -- Research, Biological sciences, Chemistry
Abstract

Research has been conducted on N-nitrosoguanidines. The results of the kinetic study of the compounds' hydrolysis are reported.

Published
2003

Catalog

Books, media, physical & digital resources
See catalog results